The Evolution of Virtual Care in Respirology

By Staff Writer

September 13, 2023

The escalating prevalence of chronic diseases coupled with an ageing population is leading to a significant surge in demand for continuous home and institutional care. With professional resources in Québec becoming increasingly limited, virtual care tools have emerged as a crucial solution to ensure access to care and services.

The COVID-19 pandemic has accelerated the use of virtual care tools, promoting continuity of care when in-person visits became risky or impossible. These tools, ranging from telemonitoring to teleconsultation, are becoming integral to the evaluation, treatment, and follow-up of patients in specialty medicine, including respirology.

Virtual Care Modalities in Respirology

Primarily, virtual care modalities are being used to improve access to health care and foster patient engagement in managing their illness. For instance, telemonitoring is the most studied intervention in all the care pathways examined, with a positive impact reported in patients with COPD (Chronic Obstructive Pulmonary Disease) and asthma. Telemonitoring, the most studied intervention, has shown positive effects in COPD and asthma patients. 


The potential of virtual care is vast. It can reduce symptoms of disease, decrease anxiety, improve disease management, and enhance the quality of life for patients. Furthermore, it can support primary care physicians in diagnosing diseases like COPD and asthma, thereby preventing misdiagnosis.

Challenges and Future Directions

Despite the promising results, there is a need for more high-quality studies to further explore the efficacy of virtual care interventions. Areas that need further investigation include the long-term efficacy of virtual care in terms of medication adherence and the use of virtual care for diseases like cystic fibrosis and chronic respiratory failure.

In conclusion, the most studied care pathway for the use of virtual care in respirology is for COPD, with telemonitoring being the most frequently used modality. As we continue to navigate the digital health landscape, the revolution of the respirology field is set to occur through the integration of virtual care modalities into care pathways.

Reference url

Recent Posts

preventive health costs
       

Prevention Valuation: Fund Health, Not Just Savings

💡 Is prevention really saving us money in healthcare?

In their thought-provoking article, “Can Prevention Save Money?”, Baicker and Chandra challenge the prevailing notion that preventive health measures always reduce costs. They argue that while prevention can enhance health outcomes, it often leads to increased spending upfront, and the key lies in evaluating these programs based on their cost-effectiveness instead of expecting them to save money outright.

Curious about the real financial implications of preventive care? Dive into the full analysis to uncover the nuances!

#SyenzaNews #HealthEconomics #costeffectiveness #healthcarepolicy

FDA AI Drug Approval
          

FDA AI Drug Approval

🚀 Are we on the brink of a new era in drug approval?

The FDA’s new AI initiative is set to reshape how we evaluate new therapies by dramatically speeding up the review process. With generative AI tools already cutting down review times from days to mere minutes, this breakthrough will not only enhance efficiency but also enable scientists to focus on more impactful work.

Curious about the implications for market access, patient outcomes, and health economics? Dive into the full article to explore how the future of pharmaceutical approvals is being transformed!

#SyenzaNews #regulatoryaffairs #AIinHealthcare #innovation

HCV treatment advancements
      

HCV Treatment Advancements: Atea Pharmaceuticals KOL Panel

🌍 Are we on the brink of a new era in Hepatitis C treatment?

Atea Pharmaceuticals is hosting a virtual KOL panel on May 14, 2025, featuring top experts discussing the challenges faced by HCV patients and sharing insights from the promising results of their Phase 2 study on bemnifosbuvir and ruzasvir. This could be a game-changer in advancing HCV treatments through ongoing Phase 3 trials.

Don’t miss out on how these developments might reshape the future landscape for HCV patients! Click to read more about the panel and the innovative therapies in the pipeline.

#SyenzaNews #biotechnology #HealthEconomics

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.